Company intelligence / Profile preview

Genetrix

Madrid, Madrid, Spain

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Genetrix's primary asset, Cx601 (Alofisel/Darvadstrocel), developed through its subsidiary Cellerix and later TiGenix, showed positive results in the Phase III ADMIRE-CO trial for treating Crohn's disease patients with complex perianal fistulas. The compound received European Medicines Agency approval in March 2018[1].

Therapeutic areas: ImmunologyDermatologyGastroenterology
Modalities: Humanized monoclonal antibodyCell therapy
Industry: Biotech

Partnerships

Pharmacia-UpjohnTakeda Pharmaceutical Company LimitedVentechLSPYsiosRoche GeneraAyGNovartis

Beyond the preview

Go deeper on Genetrix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genetrix.

Explore the full profile